Healthcare provider profile · identity verified

Melissa Bartling, M.D.

Family Practice · GREGORY, SD · NPI 1427017607

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Lisinopril	Lisinopril	251	53
Furosemide	Furosemide	245	47
Omeprazole	Omeprazole	243	45
Levothyroxine Sodium	Levothyroxine Sodium	241	50
Potassium Chloride	Potassium Chloride	190	37
Metoprolol Succinate	Metoprolol Succinate	139	26
Atorvastatin Calcium	Atorvastatin Calcium	131	28
Gabapentin	Gabapentin	128	26
Amlodipine Besylate	Amlodipine Besylate	119	31
Simvastatin	Simvastatin	111	22
Rosuvastatin Calcium	Rosuvastatin Calcium	98	30
Tamsulosin Hcl	Tamsulosin Hcl	95	20
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	94	19
Lorazepam	Lorazepam	89	12
Tramadol Hcl	Tramadol Hcl	86	19
Eliquis	Apixaban	77	13
Donepezil Hcl	Donepezil Hcl	75	suppressed
Metformin Hcl	Metformin Hcl	68	16
Montelukast Sodium	Montelukast Sodium	64	suppressed
Hydrochlorothiazide	Hydrochlorothiazide	63	19
Losartan Potassium	Losartan Potassium	63	22
Sertraline Hcl	Sertraline Hcl	63	16
Pregabalin	Pregabalin	59	suppressed
Carvedilol	Carvedilol	58	16
Fluticasone Propionate	Fluticasone Propionate	55	15
Oxybutynin Chloride	Oxybutynin Chloride	51	suppressed
Albuterol Sulfate Hfa	Albuterol Sulfate	49	11
Xarelto	Rivaroxaban	48	suppressed
Metoprolol Tartrate	Metoprolol Tartrate	47	12
Warfarin Sodium	Warfarin Sodium	46	suppressed
Pantoprazole Sodium	Pantoprazole Sodium	44	15
Trazodone Hcl	Trazodone Hcl	44	suppressed
Famotidine	Famotidine	43	suppressed
Citalopram Hbr	Citalopram Hydrobromide	41	11
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	40	suppressed
Allopurinol	Allopurinol	37	suppressed
Gemfibrozil	Gemfibrozil	37	suppressed
Prednisone	Prednisone	37	29
Venlafaxine Hcl Er	Venlafaxine Hcl	37	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	35	suppressed
Meloxicam	Meloxicam	35	suppressed
Topiramate	Topiramate	35	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	34	suppressed
Duloxetine Hcl	Duloxetine Hcl	34	suppressed
Mirtazapine	Mirtazapine	33	suppressed
Clopidogrel	Clopidogrel Bisulfate	30	suppressed
Celecoxib	Celecoxib	29	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	27	11
Quetiapine Fumarate	Quetiapine Fumarate	27	suppressed
Ropinirole Hcl	Ropinirole Hcl	27	suppressed
Cephalexin	Cephalexin	26	15
Myrbetriq	Mirabegron	26	suppressed
Levetiracetam	Levetiracetam	25	suppressed
Carbidopa-Levodopa	Carbidopa/Levodopa	24	suppressed
Clonazepam	Clonazepam	24	suppressed
Fenofibrate	Fenofibrate	24	suppressed
Metformin Hcl Er	Metformin Hcl	24	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	24	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	23	suppressed
Restasis	Cyclosporine	23	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	22	18
Triamcinolone Acetonide	Triamcinolone Acetonide	22	13
Alprazolam	Alprazolam	21	suppressed
Baclofen	Baclofen	20	suppressed
Finasteride	Finasteride	20	suppressed
Sucralfate	Sucralfate	20	suppressed
Azelastine Hcl	Azelastine Hcl	19	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	19	suppressed
Pravastatin Sodium	Pravastatin Sodium	19	suppressed
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	18	suppressed
Ventolin Hfa	Albuterol Sulfate	18	suppressed
Glipizide Er	Glipizide	17	suppressed
Jardiance	Empagliflozin	17	suppressed
Lantus	Insulin Glargine,hum.Rec.Anlog	17	suppressed
Nystatin	Nystatin	17	suppressed
Budesonide-Formoterol Fumarate	Budesonide/Formoterol Fumarate	16	suppressed
Atenolol	Atenolol	15	suppressed
Boostrix Tdap	Diphth,pertuss(Acell),tet Vac	15	15
Estradiol	Estradiol	15	suppressed
Januvia	Sitagliptin Phosphate	15	suppressed
Memantine Hcl	Memantine Hcl	15	suppressed
Oxycodone Hcl	Oxycodone Hcl	15	suppressed
Risperidone	Risperidone	15	suppressed
Arexvy	Rsvpref3 Antigen/As01e/Pf	14	14
Arnuity Ellipta	Fluticasone Furoate	14	suppressed
Bumetanide	Bumetanide	14	suppressed
Diclofenac Sodium	Diclofenac Sodium	14	suppressed
Ezetimibe	Ezetimibe	14	suppressed
Nifedipine Er	Nifedipine	14	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	14	suppressed
Ozempic	Semaglutide	14	suppressed
Paroxetine Hcl	Paroxetine Hcl	14	suppressed
Tresiba	Insulin Degludec	14	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	13	13
Armour Thyroid	Thyroid,pork	13	suppressed
Azithromycin	Azithromycin	13	suppressed
Carisoprodol	Carisoprodol	13	suppressed
Hydrocortisone	Hydrocortisone	13	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	13	suppressed
Oxycontin	Oxycodone Hcl	13	suppressed
Penicillin V Potassium	Penicillin V Potassium	13	suppressed
Spironolactone	Spironolactone	13	suppressed
Tresiba Flextouch U-200	Insulin Degludec	13	suppressed
Ultra-Fine Short Pen Needle	Pen Needle, Diabetic	13	suppressed
Aripiprazole	Aripiprazole	12	suppressed
Glipizide	Glipizide	12	suppressed
Hydroxychloroquine Sulfate	Hydroxychloroquine Sulfate	12	suppressed
Nitroglycerin	Nitroglycerin	12	11
Rybelsus	Semaglutide	12	suppressed
Shingrix	Varicella-Zoster Ge/As01b/Pf	12	suppressed
Sulfasalazine	Sulfasalazine	12	suppressed
Tolterodine Tartrate Er	Tolterodine Tartrate	12	suppressed
Breo Ellipta	Fluticasone/Vilanterol	11	suppressed
Dulera	Mometasone/Formoterol	11	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	11	suppressed
Testosterone Cypionate	Testosterone Cypionate	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error